Agreement Focuses on Development of Clinical Specimen Repositories, Laboratory Services, and Research.
MRIGlobal and the University of Maryland School of Medicine today announced an intention to collaborate in the development of clinical specimen repositories, laboratory services for clinical trials, and research opportunities. The work will be performed under the collaboration agreement by MRIGlobal Dx, a division of MRIGlobal.
The non-exclusive memo of understanding has an initial two-year term, with annual renewals ongoing. Other terms of the agreement were not released.
With the agreement, the University of Maryland School of Medicine and MRIGlobal Dx plan to explore opportunities for procurement of clinical samples and patient specimen collection and banking.
Researchers in molecular and translational medicine use specimen repositories to develop new ways to diagnose, prevent, or treat diseases. Specimens may include fluids, tissues, tumors, cells and genetic material.
"This is a powerful agreement between two organizations committed to excellence and advancing knowledge," said Thomas M. Sack, Ph.D., President and Chief Executive Officer of MRIGlobal. "We are delighted to collaborate with the University of Maryland School of Medicine in bringing new diagnostic products and therapeutics to market."
University of Maryland School of Medicine Dean E. Albert Reece, who is Vice President for Medical Affairs at the University of Maryland and the John Z. and Akiko Bowers Distinguished Professor at the School of Medicine, commented: "As we continue to develop our resources as a top biomedical research institution, this agreement provides a critical service for our laboratories and clinical trials.
"We are excited to partner with a leading firm like MRIGlobal in this endeavor," he said.
For more information, visit www.mriglobaldx.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.